[go: up one dir, main page]

NO20050985L - 3-z-(1-(4-(n-((4-4metyl-piperazin-1-yl)-metylkarbonyl)- n-metyl-amino)-anilino)-1-fenyl-metylen)-6-metoksykarb onyl-2-indolinon-monoetansulfonat og anvendelse derav - Google Patents

3-z-(1-(4-(n-((4-4metyl-piperazin-1-yl)-metylkarbonyl)- n-metyl-amino)-anilino)-1-fenyl-metylen)-6-metoksykarb onyl-2-indolinon-monoetansulfonat og anvendelse derav

Info

Publication number
NO20050985L
NO20050985L NO20050985A NO20050985A NO20050985L NO 20050985 L NO20050985 L NO 20050985L NO 20050985 A NO20050985 A NO 20050985A NO 20050985 A NO20050985 A NO 20050985A NO 20050985 L NO20050985 L NO 20050985L
Authority
NO
Norway
Prior art keywords
4methyl
methylcarbonyl
anilino
piperazin
methoxycarbonyl
Prior art date
Application number
NO20050985A
Other languages
English (en)
Other versions
NO330486B1 (no
Inventor
Guenter Linz
Peter Sieger
Gerald Juergen Roth
Frank Hilberg
Werner Rall
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050985(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20050985L publication Critical patent/NO20050985L/no
Publication of NO330486B1 publication Critical patent/NO330486B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20050985A 2002-07-24 2005-02-23 3-z-(1-(4-(n-((4-4metyl-piperazin-1-yl)-metylkarbonyl)-n-metyl-amino)-anilino)-1-fenyl-metylen)-6-metoksykarb onyl-2-indolinon-monoetansulfonat, farmasoytisk preparat med og metbolitt av denne, fremstilling av farmasoytisk preparat og anvendelse av forbindelsen for fremstilling av farmasoytisk preparat for behandling av sykdom NO330486B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
PCT/EP2003/007822 WO2004013099A1 (en) 2002-07-24 2003-07-18 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO20050985L true NO20050985L (no) 2005-02-23
NO330486B1 NO330486B1 (no) 2011-04-26

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050985A NO330486B1 (no) 2002-07-24 2005-02-23 3-z-(1-(4-(n-((4-4metyl-piperazin-1-yl)-metylkarbonyl)-n-metyl-amino)-anilino)-1-fenyl-metylen)-6-metoksykarb onyl-2-indolinon-monoetansulfonat, farmasoytisk preparat med og metbolitt av denne, fremstilling av farmasoytisk preparat og anvendelse av forbindelsen for fremstilling av farmasoytisk preparat for behandling av sykdom

Country Status (35)

Country Link
US (2) US7119093B2 (no)
EP (2) EP1527047B1 (no)
JP (1) JP5039279B2 (no)
KR (1) KR101145691B1 (no)
CN (1) CN100351235C (no)
AR (2) AR040662A1 (no)
AT (1) ATE551322T1 (no)
AU (1) AU2003254376B2 (no)
BR (1) BRPI0312811B8 (no)
CA (1) CA2493310C (no)
CY (1) CY1112916T1 (no)
DE (1) DE10233500A1 (no)
DK (1) DK1527047T3 (no)
EA (1) EA008684B1 (no)
EC (1) ECSP055571A (no)
EG (1) EG24562A (no)
ES (1) ES2384968T3 (no)
HR (1) HRP20050070B1 (no)
IL (2) IL166405A0 (no)
ME (1) ME00353B (no)
MX (1) MXPA04012785A (no)
MY (1) MY136883A (no)
NO (1) NO330486B1 (no)
NZ (1) NZ538367A (no)
PE (1) PE20040704A1 (no)
PL (1) PL223758B1 (no)
PT (1) PT1527047E (no)
RS (1) RS52283B (no)
SA (1) SA03240446B1 (no)
SI (1) SI1527047T1 (no)
TW (1) TWI285635B (no)
UA (1) UA78352C2 (no)
UY (1) UY27904A1 (no)
WO (1) WO2004013099A1 (no)
ZA (1) ZA200409814B (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
ES2658091T3 (es) * 2007-12-03 2018-03-08 Boehringer Ingelheim International Gmbh Procedimiento para la fabricación de un derivado de indolinona
SI2985025T1 (en) * 2008-06-06 2018-04-30 Boehringer Ingelheim International Gmbh A pharmaceutical combination
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
LT2299987T (lt) 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
WO2010130758A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
JP2015524400A (ja) 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) * 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
US20190160054A1 (en) 2016-04-13 2019-05-30 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017198202A1 (zh) * 2016-05-19 2017-11-23 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
JP2019522638A (ja) 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
US20190275033A1 (en) 2016-06-01 2019-09-12 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
WO2018054077A1 (en) 2016-09-26 2018-03-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Composition for treating ocular diseases and methods of usage and making
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
WO2018160967A1 (en) * 2017-03-02 2018-09-07 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
EP3597636A4 (en) * 2017-03-14 2020-10-21 Allgenesis Biotherapeutics Inc. CRYSTALLINE FORMS OF 3-Z- [1- (4- (N - ((4-METHYL-PIPERAZIN-1-YL) -METHYLCARBONYL) -N-METHYL-AMINO) -PHENYLAMINO) -1-PHENYL-METHYLENE] -6 -METHOXYCARBONYL-2-INDOLINONE
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
JP2020512364A (ja) 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited Process for the preparation of nintedanib
EP3700529B1 (en) 2017-10-23 2025-07-09 Boehringer Ingelheim International GmbH New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019097112A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
PL3761980T3 (pl) 2018-03-07 2024-06-10 Pliant Therapeutics, Inc. Związki aminokwasowe i sposoby zastosowania
CN112423757A (zh) 2018-06-15 2021-02-26 汉达生技医药责任有限公司 激酶抑制剂的盐类及其组合物
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
WO2021198253A1 (en) 2020-04-01 2021-10-07 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
EP4149475A1 (en) 2020-05-22 2023-03-22 QX Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
AU2021321561A1 (en) * 2020-08-07 2023-03-09 Bdr Lifesciences Private Limited An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN119630395A (zh) 2022-02-28 2025-03-14 努福米克斯技术有限公司 用于治疗特发性肺纤维化的组合物和方法
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en) 2023-12-27 2025-07-02 Faran S.A. Oral suspensions comprising nintedanib esylate
KR20250118711A (ko) 2024-01-30 2025-08-06 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 생체이용률이 개선된 경구투여용 제제
WO2025261988A1 (fr) 2024-06-17 2025-12-26 Assistance Publique Hopitaux De Paris Utilisation de nintédanib pour le traitement de la maladie de castleman

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7067513B1 (en) * 1999-08-23 2006-06-27 Solvay Pharmaceuticals B.V. Phenylpiperazines
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
MXPA04012785A (es) 2005-06-08
MEP53708A (en) 2011-05-10
HRP20050070A2 (en) 2005-12-31
US20060258681A1 (en) 2006-11-16
DE10233500A1 (de) 2004-02-19
PL223758B1 (pl) 2016-10-31
BRPI0312811B8 (pt) 2021-05-25
ME00353B (me) 2011-10-10
BR0312811A (pt) 2005-04-19
CA2493310A1 (en) 2004-02-12
EP2386543A1 (en) 2011-11-16
NO330486B1 (no) 2011-04-26
AU2003254376A1 (en) 2004-02-23
IL166405A0 (en) 2006-01-15
AR094217A2 (es) 2015-07-15
UY27904A1 (es) 2004-02-27
CN1671660A (zh) 2005-09-21
DK1527047T3 (da) 2012-07-16
BRPI0312811B1 (pt) 2019-03-12
KR101145691B1 (ko) 2012-05-25
SI1527047T1 (sl) 2012-07-31
EG24562A (en) 2009-10-25
PT1527047E (pt) 2012-06-28
IL166405A (en) 2009-11-18
HRP20050070B1 (hr) 2013-09-30
PE20040704A1 (es) 2004-11-29
CY1112916T1 (el) 2016-04-13
TWI285635B (en) 2007-08-21
NZ538367A (en) 2008-01-31
MY136883A (en) 2008-11-28
WO2004013099A1 (en) 2004-02-12
ATE551322T1 (de) 2012-04-15
ECSP055571A (es) 2005-04-18
RS20050046A (sr) 2007-09-21
HK1078851A1 (zh) 2006-03-24
UA78352C2 (uk) 2007-03-15
BRPI0312811A8 (pt) 2019-01-02
US20040176392A1 (en) 2004-09-09
PL372996A1 (en) 2005-08-08
JP5039279B2 (ja) 2012-10-03
AR040662A1 (es) 2005-04-13
EP1527047A1 (en) 2005-05-04
AU2003254376B2 (en) 2010-06-17
KR20050042139A (ko) 2005-05-04
CA2493310C (en) 2011-01-18
RS52283B (sr) 2012-10-31
US7119093B2 (en) 2006-10-10
EP1527047B1 (en) 2012-03-28
EA200500146A1 (ru) 2005-08-25
EA008684B1 (ru) 2007-06-29
CN100351235C (zh) 2007-11-28
SA03240446B1 (ar) 2007-07-31
TW200409754A (en) 2004-06-16
JP2005535684A (ja) 2005-11-24
ZA200409814B (en) 2006-02-22
ES2384968T3 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
NO20050985L (no) 3-z-(1-(4-(n-((4-4metyl-piperazin-1-yl)-metylkarbonyl)- n-metyl-amino)-anilino)-1-fenyl-metylen)-6-metoksykarb onyl-2-indolinon-monoetansulfonat og anvendelse derav
NO20021341D0 (no) Autentisering og tilgangsstyring
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
DK1527067T3 (da) 4-Trifluormethylpyrazolylsubstituerede pyridiner og pyrimidiner
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
IS7546A (is) Indól, azaindól og skyld heterósýklísk 4-alkenýl píperidín amíð
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
NO20044095L (no) 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
NO20033099L (no) N-(fenylsulfonyl)glycin-derivater og deres terapeutiske anvendelse
IS8392A (is) Heterósýklískir hindrar MEK og notkun þeirra
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS2675B (is) P38-hindrar og aðferðir til notkunar þeirra
DK1554250T3 (da) Hidtil ukendt lactamer og anvendelser deraf
DK1558595T3 (da) Piperazinyl- og diazapanylbenzamider og -benzthioamider
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20043580L (no) Quinazolinonderivater og deres bruk som CB agonister
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DK1359458T3 (da) Brillestel og hængselsenhed til anvendelse deri
ITMI20020687A1 (it) Elemento di legno e procedimento per la sua realizzazione
NO20042500L (no) Chemokin-reseptorantagonister og metoder for anvendelse derav
ATE548037T1 (de) Peptid-deformylase-hemmer
ATE312077T1 (de) Peptiddeformylase-hemmer

Legal Events

Date Code Title Description
MK1K Patent expired